Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aktis Oncology Inc (AKTS)

Aktis Oncology Inc (AKTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Should You Buy PICS Stock After the PicPay IPO?

2025 was a better year for IPOs than 2024. More than 200 companies raised about $33.6 billion, up from 150 companies and roughly $30 billion the year before. Although the tech theme dominated, thanks to the wider AI trade, names from the healthcare, industrials, and energy sectors also made a splash. “More of the same” seems to be the theme for 2026, as the AI buildout gets stronger and stronger.

However, 2026 has not yet seen a blockbuster tech IPO. In fact, among the names that have made their debut on the bourses, the biggest one has been that of the biotech company, Aktis Oncology (AKTS). Following...

Fundamentals

See More
  • Market Capitalization, $K 1,095,031
  • Shares Outstanding, K 50,649
  • Annual Sales, $ 27,380 K
  • Annual Income, $ -167,950 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 204.23
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/11/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +42.11%

Most Recent Stories

More News
Should You Buy PICS Stock After the PicPay IPO?

The Brazilian fintech company is purportedly set to trade from Jan. 29.

AKTS : 21.22 (-1.85%)
NU : 18.55 (+2.04%)
MarketBeat Week in Review – 01/12 - 01/16

Economic data helped stocks move higher as it showed that the Fed's decision on interest rates may not interrupt the bullish case for equities in 2026.

NFLX : 85.57 (-0.15%)
META : 673.11 (+0.11%)
GOOGL : 334.55 (+0.39%)
NVDA : 188.51 (+1.09%)
AAPL : 258.27 (+1.12%)
AVGO : 332.79 (+2.44%)
GLXY : 33.18 (+6.07%)
DAL : 66.14 (-2.01%)
TSM : 338.34 (+1.69%)
AKTX : 0.2745 (+0.84%)
COST : 970.28 (-0.76%)
TSLA : 430.91 (-0.99%)
A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

SFD : 23.78 (+0.98%)
CRWV : 108.86 (+10.73%)
AKTS : 21.22 (-1.85%)
LLY : 1,039.51 (-2.19%)
MDLN : 46.27 (+3.19%)
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...

AKTS : 21.22 (-1.85%)
Akoustis Technologies Enters Chapter 11 to Facilitate Strategic Sale Following Qorvo Legal Challenges

Akoustis Technologies files for Chapter 11 to facilitate a strategic sale while addressing legal issues with Qorvo.Quiver AI SummaryAkoustis Technologies, Inc. has announced that it has voluntarily filed...

AKTS : 21.22 (-1.85%)
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

AKTS : 21.22 (-1.85%)
Zacks Industry Outlook Highlights RF Industries and Akoustis

For Immediate ReleaseChicago, IL – December 10, 2024 – Today, Zacks Equity Research discusses RF Industries RFIL and Akoustis Technologies AKTS.Industry: Radio-Frequency SemiconductorsLink: https://www.zacks.com/commentary/2380991/2-radio-frequency-stocks-to-watch-in-a-challenging-industryThe...

RFIL : 10.86 (+1.12%)
AKTS : 21.22 (-1.85%)
2 Radio Frequency Stocks to Watch in a Challenging Industry

The Zacks Semiconductors - Radio Frequency industry participants are suffering from a challenging demand environment, primarily attributed to a suspension in capital spending by telecom carriers. Industry...

RFIL : 10.86 (+1.12%)
AKTS : 21.22 (-1.85%)
Akoustis: Fiscal Q1 Earnings Snapshot

Akoustis: Fiscal Q1 Earnings Snapshot

AKTS : 21.22 (-1.85%)
Akoustis Gains on New Purchase Order

Akoustis Technologies, Inc. (NASDAQ: AKTS) shares were in the green Tuesday. The integrated device manufacturer ...

AKTS : 21.22 (-1.85%)

Business Summary

Aktis Oncology Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis Oncology Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 24.37
2nd Resistance Point 23.18
1st Resistance Point 22.40
Last Price 21.22
1st Support Level 20.43
2nd Support Level 19.24
3rd Support Level 18.46

See More

52-Week High 29.16
Fibonacci 61.8% 25.10
Fibonacci 50% 23.84
Fibonacci 38.2% 22.58
Last Price 21.22
52-Week Low 18.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar